Recent Progress of Src SH2 and SH3 Inhibitors as Anticancer Agents

Author(s): X.-L. Lu, X. Cao, X.-Y. Liu, B.-H. Jiao.

Journal Name: Current Medicinal Chemistry

Volume 17 , Issue 12 , 2010

Become EABM
Become Reviewer

Abstract:

Src family tyrosine kinases (SFKs) play key roles in regulating signal transduction in cellular processes. However, hyper-activated SFKs lead to uncontrolled cell proliferation and cancers. For both Src SH2 and SH3 domains involve in the regulation of tumorigenesis signal pathways, the SH2 and SH3 inhibition strategies are expected to block the protein-protein interactions between SFKs and their corporation proteins to abolish the signal transduction. Many inhibitors of SH2 and SH3 domain have been identified. Herein, some predominant examples of these inhibitors are reviewed.

Keywords: Protein tyrosine kinases, Src kinases, SH2, SH3, inhibitor, peptidomimetic, nonpeptide, progress

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 12
Year: 2010
Page: [1117 - 1124]
Pages: 8
DOI: 10.2174/092986710790827861
Price: $58

Article Metrics

PDF: 14